HC Wainwright Issues Pessimistic Outlook for CRVS Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Investment analysts at HC Wainwright lowered their FY2026 earnings estimates for Corvus Pharmaceuticals in a research note issued on Wednesday, November 11th. HC Wainwright analyst S. Lee now anticipates that the company will post earnings per share of ($0.86) for the year, down from their prior estimate of ($0.83). The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ Q4 2026 earnings at ($0.25) EPS, Q1 2027 earnings at ($0.25) EPS, Q2 2027 earnings at ($0.26) EPS, Q3 2027 earnings at ($0.26) EPS, Q4 2027 earnings at ($0.26) EPS, FY2027 earnings at ($1.04) EPS, FY2028 earnings at ($0.90) EPS, FY2029 earnings at ($0.43) EPS and FY2030 earnings at $0.45 EPS.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03).

A number of other equities analysts also recently weighed in on the stock. Ladenburg Thalmann & Co. Inc. upgraded shares of Corvus Pharmaceuticals to a “strong-buy” rating in a report on Thursday, July 30th. Wall Street Zen lowered shares of Corvus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, November 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Corvus Pharmaceuticals in a report on Wednesday, September 16th. Mizuho set a $27.00 price objective on Corvus Pharmaceuticals in a research note on Thursday, October 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a research note on Monday, October 26th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $32.83.

Corvus Pharmaceuticals Stock Performance

NASDAQ:CRVS opened at $10.62 on Friday. The stock’s 50-day simple moving average is $11.26 and its 200 day simple moving average is $14.10. The company has a market cap of $895.80 million, a P/E ratio of -14.96 and a beta of 1.57. Corvus Pharmaceuticals has a 52-week low of $6.39 and a 52-week high of $26.95.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. The Manufacturers Life Insurance Company lifted its position in Corvus Pharmaceuticals by 481.7% during the first quarter. The Manufacturers Life Insurance Company now owns 101,779 shares of the company’s stock worth $1,489,000 after purchasing an additional 84,282 shares during the period. DCF Advisers LLC acquired a new stake in Corvus Pharmaceuticals during the second quarter worth about $9,524,000. Blue Owl Capital Holdings LP acquired a new stake in Corvus Pharmaceuticals during the second quarter worth about $9,092,000. Renaissance Technologies LLC bought a new position in Corvus Pharmaceuticals in the 1st quarter valued at about $1,190,000. Finally, Bank of America Corp DE bought a new position in Corvus Pharmaceuticals in the 2nd quarter valued at about $11,322,000. Institutional investors own 46.64% of the company’s stock.

Key Stories Impacting Corvus Pharmaceuticals

Investors following CRVS have been watching these stories:

• Negative Sentiment: HC Wainwright lowered its EPS forecasts across multiple periods, including FY2026 to a loss of $0.86 per share from $0.83, FY2027 to a loss of $1.04 from $0.80, and FY2028 to a loss of $0.90 from $0.37. Estimates for several 2027 quarters were also cut. Its FY2030 forecast still implies a profit, but was reduced to $0.45 per share from $0.67. The broad revisions point to weaker expected earnings and a longer path to profitability. Corvus Pharmaceuticals analyst estimates

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines that target the immune system to treat cancer and immune-related diseases. The company is based in Burlingame, California, and its work centers on therapies in clinical development rather than marketed products. Its lead candidate, soquelitinib (also known as CPI-818), is an oral inhibitor of interleukin-2-inducible T-cell kinase, or ITK. Corvus is developing the drug for T-cell lymphoma and has also explored its potential in inflammatory and autoimmune conditions, including atopic dermatitis.